Endo International PLC’s (ENDP) “Buy” Rating Reaffirmed at JMP Securities
A number of other research firms have also recently weighed in on ENDP. Oppenheimer Holdings Inc. reaffirmed a hold rating on shares of Endo International PLC in a report on Tuesday, November 8th. Piper Jaffray Cos. reaffirmed a neutral rating and issued a $19.00 price objective on shares of Endo International PLC in a report on Tuesday, September 27th. BMO Capital Markets reaffirmed a hold rating on shares of Endo International PLC in a report on Friday, November 11th. Royal Bank Of Canada cut their price objective on shares of Endo International PLC from $26.00 to $21.00 and set an outperform rating for the company in a report on Wednesday, November 9th. Finally, Mizuho raised shares of Endo International PLC from a neutral rating to a buy rating and lifted their price objective for the company from $16.00 to $29.00 in a report on Friday, August 12th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $31.63.
Shares of Endo International PLC (NASDAQ:ENDP) traded down 0.496% during mid-day trading on Friday, hitting $17.055. 725,780 shares of the stock traded hands. Endo International PLC has a 12 month low of $12.56 and a 12 month high of $63.71. The company’s market cap is $3.80 billion. The firm has a 50 day moving average of $19.00 and a 200 day moving average of $18.70.
Endo International PLC (NASDAQ:ENDP) last issued its earnings results on Tuesday, November 8th. The company reported $1.01 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.81 by $0.20. Endo International PLC had a negative net margin of 3.32% and a positive return on equity of 15.95%. The firm earned $894.30 million during the quarter, compared to analysts’ expectations of $862.47 million. During the same quarter last year, the company posted $1.02 earnings per share. The firm’s revenue was up 18.6% compared to the same quarter last year. Equities analysts anticipate that Endo International PLC will post $4.60 EPS for the current fiscal year.
In other news, Director Roger H. Kimmel sold 14,000 shares of the stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $17.38, for a total value of $243,320.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.70% of the stock is currently owned by insiders.
Several institutional investors have recently made changes to their positions in the stock. Cognios Capital LLC bought a new position in shares of Endo International PLC during the third quarter worth about $1,273,000. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Endo International PLC by 17.7% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 778,863 shares of the company’s stock worth $15,694,000 after buying an additional 116,899 shares in the last quarter. Xact Kapitalforvaltning AB bought a new position in shares of Endo International PLC during the third quarter worth about $649,000. Panagora Asset Management Inc. increased its position in shares of Endo International PLC by 678.0% in the third quarter. Panagora Asset Management Inc. now owns 270,977 shares of the company’s stock worth $5,460,000 after buying an additional 236,149 shares in the last quarter. Finally, Acrospire Investment Management LLC increased its position in shares of Endo International PLC by 139.3% in the third quarter. Acrospire Investment Management LLC now owns 7,897 shares of the company’s stock worth $159,000 after buying an additional 4,597 shares in the last quarter. Institutional investors and hedge funds own 96.71% of the company’s stock.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.